Drugs / Personalized Neoantigen Peptide Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07002203 | Mar 2024 → Aug 2027 expected | cancer | Seqker Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06614140 | Nov 2022 → Aug 2025 | cancer | Seqker Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Personalized Neoantigen Peptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07002203 ↗ |
| Known as | neoantigen peptide vaccine | “This clinical trial is studying the safety and efficacy of a personalized cancer vaccine called a neoantigen peptide vaccine in patients with solid tumors.” NCT07002203 ↗ |
| Modality | Vaccine | “personalized neoantigen peptide vaccine” NCT06614140 ↗ |
| Route | Intramuscular | “The peptides are administered intramuscularly in combination with poly-ICLC (Hiltonol) as an adjuvant to enhance immune response.” NCT07002203 ↗ |